nach oben

Familial Cancer

Erschienen in:

16.09.2017 | Original Article

Mutations in context: implications of BRCA testing in diverse populations

verfasst von: Gabriela E. S. Felix, Yonglan Zheng, Olufunmilayo I. Olopade

Erschienen in: Familial Cancer | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Cancer is a common non-communicable disease worldwide, although it exhibits differential population trends in incidence and mortality rates. The differences relate to population structure, environmental risk factors as well as health system organization. This article discusses the potential impact of genetic testing on population health, focusing in particular on the mutational spectrum of breast cancer susceptibility genes in diverse populations. We identify the need for improved access to, and increased investment in, comprehensive cancer risk assessment and genetic testing as well as cancer control measures that take into account lifestyle, environmental, and social factors in understudied minority groups.

WHO (2014) Global status report on noncommunicable diseases 2014. World Health. doi: ISBN 9789241564854

Skol AD, Sasaki MM, Onel K (2016) The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance. Breast Cancer Res 18:99. doi: 10.1186/s13058-016-0759-4 CrossRefPubMedPubMedCentral

Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372:793–795. doi: 10.1056/NEJMp1500523 CrossRefPubMedPubMedCentral

Mardis ER (2008) Next-generation DNA sequencing methods. Annu Rev Genom Hum Genet 9:387–402. doi: 10.1146/annurev.genom.9.081307.164359 CrossRef

Mardis ER (2008) The impact of next-generation sequencing technology on genetics. Trends Genet 24:133–141. doi: 10.1016/j.tig.2007.12.007 CrossRefPubMed

Royal CD, Novembre J, Fullerton SM et al (2010) Inferring genetic ancestry: opportunities, challenges, and implications. Am J Hum Genet 86:661–673. doi: 10.1016/j.ajhg.2010.03.011 CrossRefPubMedPubMedCentral

Hall JM, Lee MK, Newman B et al (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684–1689. doi: 10.1126/science.2270482 CrossRefPubMed

Wooster R, Neuhausen S, Mangion J et al (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265:2088–2090. doi: 10.1126/science.8091231 CrossRefPubMed

Pal T, Bonner D, Cragun D et al (2015) A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. Cancer 121:4173–4180. doi: 10.1002/cncr.29645 CrossRefPubMed

10.

Milne RL, Antoniou AC (2016) Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. Endocr Relat Cancer 23:T69–T84. doi: 10.1530/ERC-16-0277 CrossRefPubMed

11.

Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402. doi: 10.1001/jama.2017.7112 CrossRefPubMed

12.

Petrucelli N, Daly MB, Feldman GL (2013) BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer

13.

Robertson L, Hanson H, Seal S et al (2012) BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 106:1234–1238. doi: 10.1038/bjc.2012.31 CrossRefPubMedPubMedCentral

14.

Mahfoudh W, Bouaouina N, Ahmed S, Ben et al (2012) Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep 39:1037–1046. doi: 10.1007/s11033-011-0829-8 CrossRefPubMed

15.

Janavičius R (2010) Founder BRCA1/2 mutations in the Europe: Implications for hereditary breast-ovarian cancer prevention and control. EPMA J 1:397–412. doi: 10.1007/s13167-010-0037-y CrossRefPubMedPubMedCentral

16.

Ashton-Prolla P, Vargas FR (2014) Prevalence and impact of founder mutations in hereditary breast cancer in Latin America. Genet Mol Biol 37:234–240. doi: 10.1590/S1415-47572014000200009 CrossRefPubMed

17.

Wong-Brown MW, Meldrum CJ, Carpenter JE et al (2015) Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat 150:71–80. doi: 10.1007/s10549-015-3293-7 CrossRefPubMed

18.

Shanmughapriya S, Nachiappan V, Natarajaseenivasan K (2013) BRCA1 and BRCA2 mutations in the ovarian cancer population across race and ethnicity: special reference to Asia. Oncology 84:226–232. doi: 10.1159/000346593 CrossRefPubMed

19.

Struewing J, Abeliovich D, Peretz T et al (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198–200. doi: 10.1038/ng1096-188 CrossRefPubMed

20.

Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408. doi: 10.1056/NEJM199705153362001 CrossRefPubMed

21.

Ewald IP, Izetti P, Vargas FR et al (2011) Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome. Hered Cancer Clin Pract 9:12. doi: 10.1186/1897-4287-9-12 CrossRefPubMedPubMedCentral

22.

Dillenburg CV, Bandeira IC, Tubino TV et al (2012) Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil. Genet Mol Biol 35:599–602. doi: 10.1590/S1415-47572012000400009 CrossRefPubMedPubMedCentral

23.

John EM, Miron A, Gong G et al (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298:2869–2876. doi: 10.1016/S0084-3954(08)79042-0 CrossRefPubMed

24.

Weitzel JN, Lagos V, Blazer KR et al (2005) Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 14:1666–1671. doi: 10.1158/1055-9965.EPI-05-0072 CrossRefPubMed

25.

Hamel N, Feng B-J, Foretova L et al (2011) On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 19:300–306. doi: 10.1038/ejhg.2010.203 CrossRefPubMed

26.

Bar-Sade RB, Kruglikova a, Modan B et al (1998) The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet 7:801–805. doi: 10.1093/hmg/7.5.801 CrossRefPubMed

27.

Kehdy FSG, Gouveia MH, Machado M et al (2015) Origin and dynamics of admixture in Brazilians and its effect on the pattern of deleterious mutations. Proc Natl Acad Sci USA 112:8696–8701. doi: 10.1073/pnas.1504447112 CrossRefPubMedPubMedCentral

28.

Felix GES, Abe-Sandes K, Bonfim TM et al (2010) Ancestry informative markers and complete blood count parameters in Brazilian blood donors. Rev Bras Hematol Hemoter 32:282–285. doi: 10.1590/S1516-84842010005000074 CrossRef

29.

Lima-Costa MF, Rodrigues LC, Barreto ML et al (2015) Genomic ancestry and ethnoracial self-classification based on 5,871 community-dwelling Brazilians (The Epigen Initiative). Sci Rep 5:9812. doi: 10.1038/srep09812 CrossRefPubMedPubMedCentral

30.

Santos NPC, Ribeiro-Rodrigues EM, Ribeiro-Dos-Santos AKC et al (2010) Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel. Hum Mutat 31:184–190. doi: 10.1002/humu.21159 CrossRefPubMed

31.

Parra FC, Amado RC, Lambertucci JR et al (2003) Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 100:177–182. doi: 10.1073/pnas.0126614100 CrossRefPubMed

32.

IBGE (2007) IBGE | Memória | publicações | Brasil: 500 anos de povoamento. http://memoria.ibge.gov.br/publicacoes/brasil-500-anos-de-povoamento.html. Accessed 9 May 2016

33.

Dufloth RM, Carvalho S, Heinrich JK et al (2005) Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. Sao Paulo Med J 123:192–197. doi: 10.1590/S1516-31802005000400007 CrossRefPubMed

34.

Felix GE, Abe-Sandes C, Machado-Lopes TM et al (2014) Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population. Hum Genome Var 1:14012. doi: 10.1038/hgv.2014.12 CrossRefPubMedPubMedCentral

35.

Esteves VF, Thuler LCS, Amêndola LC et al (2009) Prevalence of BRCA1 and BRCA2 gene mutations in families with medium and high risk of breast and ovarian cancer in Brazil. Braz J Med Biol Res 42:453–457. doi: 10.1590/S0100-879X2009000500009 CrossRefPubMed

36.

Gomes MCB, Costa MM, Borojevic R et al (2007) Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 103:349–353. doi: 10.1007/s10549-006-9378-6 CrossRefPubMed

37.

Silva FC, Lisboa BC, Figueiredo MC et al (2014) Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. BMC Med Genet 15:55. doi: 10.1186/1471-2350-15-55 CrossRefPubMedPubMedCentral

38.

da Costa ECB, Vargas FR, Moreira AS et al (2008) Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome. Cancer Genet Cytogenet 184:62–66. doi: 10.1016/j.cancergencyto.2008.03.011 CrossRefPubMed

39.

Gao Q, Neuhausen S, Cummings S et al (1997) Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet 60:1233–1236PubMedPubMedCentral

40.

Nanda R, Schumm LP, Cummings S et al (2005) Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294:1925–1933. doi: 10.1001/jama.294.15.1925 CrossRefPubMed

41.

Fackenthal JD, Zhang J, Zhang B et al (2012) High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J cancer 131:1114–1123. doi: 10.1002/ijc.27326 CrossRefPubMed

42.

Donenberg T, Lunn J, Turnquest T et al (2009) High frequency of BRCA1 founder mutations in the Bahamas. Cancer Res 69:4078–4078. doi: 10.1158/0008-5472.SABCS-09-4078 CrossRef

43.

Donenberg T, Lunn J, Curling D et al (2011) A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat 125:591–596. doi: 10.1007/s10549-010-1156-9 CrossRefPubMed

44.

Akbari M, Donenberg T, Lunn J et al (2014) The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas. Clin Genet 85:64–67. doi: 10.1111/cge.12132 CrossRefPubMed

45.

Donenberg T, Ahmed H, Royer R et al (2016) A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago. Breast Cancer Res Treat 159:131–138. doi: 10.1007/s10549-016-3870-4 CrossRefPubMed

46.

Hernández JEL, Llacuachaqui M, Palacio GV et al (2014) Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Medellín, Colombia. Hered Cancer Clin Pract 12:11. doi: 10.1186/1897-4287-12-11 CrossRefPubMedPubMedCentral

47.

Torres D, Rashid MU, Gil F et al (2007) High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 103:225–232. doi: 10.1007/s10549-006-9370-1 CrossRefPubMed

48.

Torres D, Bermejo JL, Rashid MU et al (2017) Prevalence and penetrance of BRCA1 and BRCA2 germline mutations in Colombian breast cancer patients. Sci Rep 7:4713. doi: 10.1038/s41598-017-05056-y CrossRefPubMedPubMedCentral

49.

Hall MJ, Reid JE, Burbidge LA et al (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115:2222–2233. doi: 10.1002/cncr.24200 CrossRefPubMed

50.

Dryja TP, Rapaport JM, Joyce JM, Petersen RA (1986) Molecular detection of deletions involving band q14 of chromosome 13 in retinoblastomas. Proc Natl Acad Sci USA 83:7391–7394CrossRefPubMedPubMedCentral

51.

Friend SH, Bernards R, Rogelj S et al (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643–646. doi: 10.1038/323643a0 CrossRefPubMed

52.

Fung YK, Murphree AL, T’Ang A et al (1987) Structural evidence for the authenticity of the human retinoblastoma gene. Science 236:1657–1661CrossRefPubMed

53.

Lee WH, Bookstein R, Hong F et al (1987) Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235:1394–1399CrossRefPubMed

54.

Kress M, May E, Cassingena R, May P (1979) Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol 31:472–483PubMedPubMedCentral

55.

Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261–263CrossRefPubMed

56.

Linzer DI, Levine AJ (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43–52CrossRefPubMed

57.

Bodmer WF, Bailey CJ, Bodmer J et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328:614–616. doi: 10.1038/328614a0 CrossRefPubMed

58.

Leppert M, Dobbs M, Scambler P et al (1987) The gene for familial polyposis coli maps to the long arm of chromosome 5. Science 238:1411–1413CrossRefPubMed

59.

Lindblom A, Tannergård P, Werelius B, Nordenskjöld M (1993) Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet 5:279–282. doi: 10.1038/ng1193-279 CrossRefPubMed

60.

Fishel R, Lescoe MK, Rao MR et al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027–1038CrossRefPubMed

61.

Leach FS, Nicolaides NC, Papadopoulos N et al (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215–1225CrossRefPubMed

62.

Bronner CE, Baker SM, Morrison PT et al (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368:258–261. doi: 10.1038/368258a0 CrossRefPubMed

63.

Papadopoulos N, Nicolaides NC, Wei YF et al (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263:1625–1629CrossRefPubMed

64.

Cannon-Albright LA, Goldgar DE, Meyer LJ et al (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258:1148–1152CrossRefPubMed

65.

Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707. doi: 10.1038/366704a0 CrossRefPubMed

66.

Kamb A, Shattuck-Eidens D, Eeles R et al (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23–26. doi: 10.1038/ng0994-22 CrossRefPubMed

67.

Kamb A, Gruis NA, Weaver-Feldhaus J et al (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440CrossRefPubMed

68.

Berx G, Staes K, van Hengel J et al (1995) Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics 26:281–289CrossRefPubMed

69.

Chen LZ, Harris PC, Apostolou S et al (1991) A refined physical map of the long arm of human chromosome 16. Genomics 10:308–312CrossRefPubMed

70.

Walsh T, Lee MK, Casadei S et al (2010) Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA 107:12629–12633. doi: 10.1073/pnas.1007983107 CrossRefPubMedPubMedCentral

71.

Churpek JE, Walsh T, Zheng Y et al (2014) Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. doi: 10.1007/s10549-014-3195-0 CrossRefPubMedPubMedCentral

72.

Cybulski C, Wokołorczyk D, Huzarski T et al (2007) A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat 102:119–122. doi: 10.1007/s10549-006-9320-y CrossRefPubMed

73.

Cybulski C, Górski B, Huzarski T et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131–1135. doi: 10.1086/426403 CrossRefPubMedPubMedCentral

74.

Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55–59. doi: 10.1038/ng879 CrossRefPubMed

75.

Friedrichsen DM, Malone KE, Doody DR et al (2004) Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women. Breast Cancer Res 6:R629-35. doi: 10.1186/bcr933 CrossRefPubMed

76.

Mateus Pereira LH, Sigurdson AJ, Doody MM et al (2004) CHEK2:1100delC and female breast cancer in the United States. Int J cancer 112:541–543. doi: 10.1002/ijc.20439 CrossRefPubMed

77.

Easton DF, Pharoah PDP, Antoniou AC et al. (2015) Gene-panel sequencing and the prediction of breast-cancer risk. 23:2243–2257

78.

King M-C, Levy-Lahad E, Lahad A et al (2014) Population-Based Screening for BRCA1 and BRCA2. JAMA 312:1091. doi: 10.1001/jama.2014.12483 CrossRefPubMed

79.

Clarke CA, Keegan THM, Yang J et al (2012) Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 104:1094–1101. doi: 10.1093/jnci/djs264 CrossRefPubMedPubMedCentral

80.

Huo D, Ikpatt F, Khramtsov A et al (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 27:4515–4521. doi: 10.1200/JCO.2008.19.6873 CrossRefPubMedPubMedCentral

81.

Huo D, Hu H, Rhie SK et al (2017) Comparison of breast cancer molecular features and survival by African and European Ancestry in the cancer genome atlas. JAMA Oncol. doi: 10.1001/jamaoncol.2017.0595 CrossRefPubMedPubMedCentral

82.

Adeniji KA, Huo D, Khramtsov A et al. (2010) Molecular profiles of breast cancer in Ilorin, Nigeria. J Clin Oncol 28:1602CrossRef

83.

Kurebayashi J, Moriya T, Ishida T et al. (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16:S72–S77CrossRefPubMed

84.

Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423. doi: 10.1073/pnas.0932692100 CrossRefPubMedPubMedCentral

85.

Grushko TA, Blackwood MA, Schumm PL et al (2002) Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 62:1481–1488PubMed

86.

Lee E, McKean-Cowdin R, Ma H et al (2011) Characteristics of triple-negative breast cancer in patients with a BRCA1 Mutation: results from a population-based study of young women. J Clin Oncol 29:4373–4380. doi: 10.1200/JCO.2010.33.6446 CrossRefPubMedPubMedCentral

87.

Mavaddat N, Barrowdale D, Andrulis IL et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21:134–147. doi: 10.1158/1055-9965.EPI-11-0775 CrossRefPubMed

88.

Tung N, Lin NU, Kidd J et al (2016) Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 34:1460–1468. doi: 10.1200/JCO.2015.65.0747 CrossRefPubMedPubMedCentral

89.

Huo D, Senie RT, Daly M et al (2009) Prediction of BRCA mutations using the BRCAPRO model in clinic-based African American, Hispanic, and other minority families in the United States. J Clin Oncol 27:1184–1190. doi: 10.1200/JCO.2008.17.5869 CrossRefPubMedPubMedCentral

90.

Fischer C, Kuchenbäcker K, Engel C et al (2013) Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J Med Genet 50:360–367. doi: 10.1136/jmedgenet-2012-101415 CrossRefPubMed

91.

J. C EM, C S-C, G. P (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689–1695. doi: 10.1158/1055-9965.EPI-13-1364 CrossRef

92.

Kurian AW, Gong GD, John EM et al (2009) Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 18:1084–1091. doi: 10.1158/1055-9965.EPI-08-1090 CrossRefPubMedPubMedCentral

93.

Hall MJ, Olopade OI (2006) Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol 24:2197–2203. doi: 10.1200/JCO.2006.05.5889 CrossRefPubMed

94.

Hall M, Olopade OI (2005) Confronting genetic testing disparities: knowledge is power. JAMA 293:1783–1785. doi: 10.1001/jama.293.14.1783 CrossRefPubMed

95.

Knudson a G (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157–162. doi: 10.1038/35101031 CrossRefPubMed

96.

King M-C (2013) Evidence is evidence: an interview with Mary-Claire King. Interviewed by Jane Gitschier. PLoS Genet 9:e1003828. doi: 10.1371/journal.pgen.1003828 CrossRefPubMed

97.

Harford JB (2011) Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all. Lancet Oncol 12:306–312. doi: 10.1016/S1470-2045(10)70273-4 CrossRefPubMed

98.

Guindalini Rodrigo Santa Cruz, Huang Yi-Ching, Obeid Elias, Patrick-Miller Linda, Bradbury Angela R., Marion S, Verp, Susan Hong, Kristen Wroblewski, Hiroyuki Abe, Greg S. Karczmar, (2013) Gillian Newstead OIO Breast cancer surveillance in high-risk women with magnetic resonance imaging every 6 months. | 2013 ASCO Annual Meeting | Abstracts | Meeting Library. J Clin Oncol 31, (suppl; abstr 1506). http://meetinglibrary.asco.org/content/114172-132. Accessed 30 Dec 2015

99.

Lancet T (2013) The failure of cancer medicine?. Lancet (Lond Engl) 381:423. doi: 10.1016/S0140-6736(13)60228-7 CrossRef

100.

Daly B, Olopade OI (2015) A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin 65:221–238. doi: 10.3322/caac.21271 CrossRefPubMed

101.

Ibrahim SS, Hafez EE, Hashishe MM (2010) Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection. J Exp Clin Cancer Res 29:82. doi: 10.1186/1756-9966-29-82 CrossRefPubMedPubMedCentral

102.

Zhang J, Fackenthal JD, Zheng Y et al (2012) Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat 134:889–894. doi: 10.1007/s10549-012-2136-z CrossRefPubMed

103.

Reeves MD, Yawitch TM, van der Merwe NC et al (2004) BRCA1 mutations in South African breast and/or ovarian cancer families: Evidence of a novel founder mutation in Afrikaner families. Int J Cancer 110:677–682. doi: 10.1002/ijc.20186 CrossRefPubMed

104.

Olopade OI, Fackenthal JD, Dunston G et al (2003) Breast cancer genetics in African Americans. Cancer 97:236–245. doi: 10.1002/cncr.11019 CrossRefPubMed

105.

Pal T, Permuth-Wey J, Holtje T, Sutphen R (2004) BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. Cancer Epidemiol Biomarkers Prev 13:1794–1799PubMed

106.

Solano AR, Aceto GM, Delettieres D et al (2012) BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. Springerplus 1:20. doi: 10.1186/2193-1801-1-20 CrossRefPubMedPubMedCentral

107.

Trottier M, Lunn J, Butler R et al (2016) Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas. Clin Genet 89:328–331. doi: 10.1111/cge.12602 CrossRefPubMed

108.

Moreira MAM, Bobrovnitchaia IG, Lima MAFD et al (2012) Portuguese c.156_157insAlu BRCA2 founder mutation: gastrointestinal and tongue neoplasias may be part of the phenotype. Fam Cancer 11:657–660. doi: 10.1007/s10689-012-9551-5 CrossRefPubMed

109.

Jara L, Ampuero S, Santibáñez E et al (2006) BRCA1 and BRCA2 mutations in a South American population. Cancer Genet Cytogenet 166:36–45. doi: 10.1016/j.cancergencyto.2005.08.019 CrossRefPubMed

110.

Jara L, Ampuero S, Seccia L et al (2002) Frequency of the 185delAG mutation in the BRCA1 gene in Chilean healthy women with family history of breast cancer. Rev médica Chile 130:1113–1123

111.

Gutiérrez Espeleta GA, Llacuachaqui M, García-Jiménez L et al (2012) BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica. Clin Genet 82:484–488. doi: 10.1111/j.1399-0004.2011.01774.x CrossRefPubMed

112.

Rodriguez RC, Esperon AA, Ropero R et al (2008) Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. Fam Cancer 7:275–279. doi: 10.1007/s10689-008-9187-7 CrossRefPubMed

113.

Tonin PN, Mes-Masson AM, Futreal PA et al (1998) Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 63:1341–1351. doi: 10.1086/302099 CrossRefPubMedPubMedCentral

114.

Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C et al (2015) Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer 121:372–378. doi: 10.1002/cncr.29058 CrossRefPubMed

115.

Abugattas J, Llacuachaqui M, Allende YS et al (2015) Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clin Genet 88:371–375. doi: 10.1111/cge.12505 CrossRefPubMed

116.

Levy-Lahad E, Catane R, Eisenberg S et al (1997) Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60:1059–1067PubMedPubMedCentral

117.

Zhang J, Pei R, Pang Z et al (2012) Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer. Breast Cancer Res Treat 132:421–428. doi: 10.1007/s10549-011-1596-x CrossRefPubMed

118.

Zhi X, Szabo C, Chopin S et al (2002) BRCA1 and BRCA2 sequence variants in Chinese breast cancer families. Hum Mutat 20:474. doi: 10.1002/humu.9083 CrossRefPubMed

119.

Li W-F, Hu Z, Rao N-Y et al (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110:99–109. doi: 10.1007/s10549-007-9708-3 CrossRefPubMed

120.

Hadjisavvas A, Charalambous E, Adamou A et al (2004) Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation. Cancer Genet Cytogenet 151:152–156. doi: 10.1016/j.cancergencyto.2003.09.020 CrossRefPubMed

121.

Vaidyanathan K, Lakhotia S, Ravishankar HM et al (2009) BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation. J Biosci 34:415–422CrossRefPubMed

122.

Saxena S, Szabo CI, Chopin S et al (2002) BRCA1 and BRCA2 in Indian breast cancer patients. Hum Mutat 20:473–474. doi: 10.1002/humu.9082 CrossRefPubMed

123.

Sekine M, Nagata H, Tsuji S et al (2001) Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population. Clin Cancer Res 7:3144–3150PubMed

124.

Liede A, Malik IA, Aziz Z et al (2002) Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 71:595–606CrossRefPubMedPubMedCentral

125.

Laitman Y, Feng B-J, Zamir IM et al (2013) Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet 21:212–216. doi: 10.1038/ejhg.2012.124 CrossRefPubMed

126.

Bar-Sade RB, Kruglikova A, Modan B et al (1998) The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet 7:801–805CrossRefPubMed

127.

Ginsburg O, Dinh N, To T et al (2011) Family history, BRCA mutations and breast cancer in Vietnamese women. Clin Genet 80:89–92. doi: 10.1111/j.1399-0004.2010.01545.x CrossRefPubMed

128.

Wagner TM, Möslinger RA, Muhr D et al (1998) BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int J cancer 77:354–360CrossRefPubMed

129.

Wagner T, Möslinger R, Muhr D et al (1997) Founding BRCA1 mutations in Austrian HBOC families. Eur J Cancer 33:S7. doi: 10.1016/S0959-8049(97)84398-5 CrossRef

130.

Peelen T, van Vliet M, Petrij-Bosch A et al (1997) A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60:1041–1049PubMedPubMedCentral

131.

Claes K, Machackova E, De Vos M, et al (1999) Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A>G. Dis Markers 15:69–73CrossRefPubMedPubMedCentral

132.

Zeegers MP, van Poppel F, Vlietinck R et al (2004) Founder mutations among the Dutch. Eur J Hum Genet 12:591–600. doi: 10.1038/sj.ejhg.5201151 CrossRefPubMed

133.

Verhoog LC, van den Ouweland AM, Berns E et al (2001) Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer 37:2082–2090. doi: 10.1016/s0959-8049(01)00244-1 CrossRefPubMed

134.

Huusko P, Pääkkönen K, Launonen V et al (1998) Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet 62:1544–1548. doi: 10.1086/301880 CrossRefPubMedPubMedCentral

135.

Muller D, Bonaiti-Pellié C, Abecassis J et al (2004) BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect. Fam Cancer 3:15–20. doi: 10.1023/B:FAME.0000026819.44213.df CrossRefPubMed

136.

Stoppa-Lyonnet D, Laurent-Puig P, Essioux L et al (1997) BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet 60:1021–1030PubMedPubMedCentral

137.

Van Der Looij M, Szabo C, Besznyak I et al (2000) Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J cancer 86:737–740CrossRef

138.

Thorlacius S, Sigurdsson S, Bjarnadottir H et al (1997) Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60:1079–1084PubMedPubMedCentral

139.

Johannesdottir G, Gudmundsson J, Bergthorsson JT et al (1996) High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res 56:3663–3665PubMed

140.

Palomba G, Cossu A, Friedman E et al (2007) Origin and distribution of the BRCA2-8765delAG mutation in breast cancer. BMC Cancer 7:132. doi: 10.1186/1471-2407-7-132 CrossRefPubMedPubMedCentral

141.

Scottish/Northern Irish BRCAI/BRCA2 Consortium TSIB (2003) BRCA1 and BRCA2 mutations in Scotland and Northern Ireland. Br J Cancer 88:1256–1262. doi: 10.1038/sj.bjc.6600840 CrossRef

142.

Møller P, Heimdal K, Apold J et al (2001) Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer 37:2428–2434. doi: 10.1016/S0959-8049(01)00299-4 CrossRefPubMed

143.

Heimdal K, Maehle L, Apold J et al (2003) The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur J Cancer 39:2205–2213. doi: 10.1016/s0959-8049(03)00548-3 CrossRefPubMed

144.

Brozek I, Cybulska C, Ratajska M et al (2011) Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet 52:325–330. doi: 10.1007/s13353-011-0040-6 CrossRefPubMedPubMedCentral

145.

Górski B, Byrski T, Huzarski T et al (2000) Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 66:1963–1968. doi: 10.1086/302922 CrossRefPubMedPubMedCentral

146.

Machado PM, Brandao RD, Cavaco BM et al (2007) Screening for a BRCA2 rearrangement in high-risk breast/ovarian Cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027–2034. doi: 10.1200/JCO.2006.06.9443 CrossRefPubMed

147.

Peixoto A, Santos C, Rocha P et al (2009) The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat 114:31–38. doi: 10.1007/s10549-008-9978-4 CrossRefPubMed

148.

Krylova N, Lobeiko OS, Sokolenko AP et al (2006) BRCA1 4153delA founder mutation in Russian ovarian cancer patients. Hered Cancer Clin Pract 4:193. doi: 10.1186/1897-4287-4-4-193 CrossRefPubMedPubMedCentral

149.

Pohlreich P, Zikan M, Stribrna J et al (2005) High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res 7:R728-36. doi: 10.1186/bcr1282 CrossRefPubMed

150.

Krajc M, De Grève J, Goelen G, Teugels E (2002) BRCA2 founder mutation in Slovenian breast cancer families. Eur J Hum Genet 10:879–882. doi: 10.1038/sj.ejhg.5200886 CrossRefPubMed

151.

Krajc M, Teugels E, Zgajnar J et al (2008) Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMC Med Genet 9:83. doi: 10.1186/1471-2350-9-83 CrossRefPubMedPubMedCentral

152.

Vega A, Campos B, Bressac-De-Paillerets B et al (2001) The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 17:520–521. doi: 10.1002/humu.1136 CrossRefPubMed

153.

Blay P, Santamaría I, Pitiot AS et al (2013) Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). BMC Cancer 13:243. doi: 10.1186/1471-2407-13-243 CrossRefPubMedPubMedCentral

154.

Bergman A, Einbeigi Z, Olofsson U et al (2001) The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet 9:787–793. doi: 10.1038/sj.ejhg.5200704 CrossRefPubMed

155.

Bergman A, Flodin A, Engwall Y et al (2005) A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques. Fam Cancer 4:89–96. doi: 10.1007/s10689-004-5812-2 CrossRefPubMed

Titel: Mutations in context: implications of BRCA testing in diverse populations
verfasst von: Gabriela E. S. Felix
Yonglan Zheng
Olufunmilayo I. Olopade
Publikationsdatum: 16.09.2017
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 4/2018
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-017-0038-2

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Mutations in context: implications of BRCA testing in diverse populations

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Molecular analysis of an asbestos-exposed Belgian family with a high prevalence of mesothelioma

Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience

Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk

The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome

Gene expression analysis in peripheral blood cells of patients with hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC): identification of NRF2 pathway activation

Response to letter to editor regarding published article—metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie